RT Journal Article
SR Electronic
T1 Concomitant Capecitabine with Hepatic Delivery of Drug Eluting Beads in Metastatic Colorectal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 7239
OP 7245
VO 34
IS 12
A1 OLAGUOKE AKINWANDE
A1 AMANDA MILLER
A1 DAVID HAYES
A1 RYAN O'HARA
A1 DANA TOMALTY
A1 ROBERT C.G. MARTIN
YR 2014
UL http://ar.iiarjournals.org/content/34/12/7239.abstract
AB Background: Effectiveness and toxicity of transcatheter arterial injection of irinotecan-eluting beads (DEBIRI) with and without concurrent capecitabine in pre-treated patients with metastatic colorectal cancer (CRC). Patients and Methods: An Institutional Review Board-approved, multi-institutional registry from 5/2008 to 8/2013 was reviewed. Patients who received DEBIRI with (X-DEBIRI) or without (DEBIRI) capecitabine were compared. Results: Twenty-two X-DEBIRI and 149 DEBIRI patients were compared. There was no difference in the two groups with regards to adverse events (p=0.56). During a 3- and 6-month evaluation, the disease control rate (DCR) was similar in both groups. During the 12-month evaluation, there was better DCR in the X-DEBIRI group (p=0.03). Median survival was 13 months in the DEBIRI group and 22 months in the X-DEBIRI group (log-rank test, p=0.217). Conclusion: There is no additional toxicity when adding capecitabine with DEBIRI. Concurrent capecitabine may offer more durable disease control rate compared to DEBIRI-alone. Survival benefit with concurrent capecitabine was not statistically significant but there may be a trend towards improved survival.